Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30146% above fair value
$25.74−0.55 (-2.09%)
Close on Nov 20, 2026Market cap $12.86BP/E –Yield –
Elanco Animal Health free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Elanco Animal Health's free cash flow for the twelve months ending Jun 30, 2026 was $379.00M, up 5.0% year over year. For fiscal 2025 it was $284.00M, down 27.9% from the year before. The highest annual figure on record is $394.00M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.00M | -27.9% |
| FY2024 | Dec 31, 2024 | $394.00M | +200.8% |
| FY2023 | Dec 31, 2023 | $131.00M | -53.4% |
| FY2022 | Dec 31, 2022 | $281.00M | -13.3% |
| FY2021 | Dec 31, 2021 | $324.00M | – |
| FY2020 | Dec 31, 2020 | -$176.00M | -309.5% |
| FY2019 | Dec 31, 2019 | $84.00M | -76.2% |
| FY2018 | Dec 31, 2018 | $352.80M | +369.1% |
| FY2017 | Dec 31, 2017 | $75.20M | +64.9% |
| FY2016 | Dec 31, 2016 | $45.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $244.00M | +35.6% |
| Q1 FY2026 | Mar 31, 2026 | -$38.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $46.00M | -64.6% |
| Q3 FY2025 | Sep 30, 2025 | $127.00M | +5.8% |
| Q2 FY2025 | Jun 30, 2025 | $180.00M | +8.4% |
| Q1 FY2025 | Mar 31, 2025 | -$69.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $130.00M | +12.1% |
| Q3 FY2024 | Sep 30, 2024 | $120.00M | -27.3% |
| Q2 FY2024 | Jun 30, 2024 | $166.00M | +773.7% |
| Q1 FY2024 | Mar 31, 2024 | -$22.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $116.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $165.00M | +1.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.00M | -93.4% |
| Q1 FY2023 | Mar 31, 2023 | -$169.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$87.00M | -170.2% |
| Q3 FY2022 | Sep 30, 2022 | $163.00M | +154.7% |
| Q2 FY2022 | Jun 30, 2022 | $286.00M | +116.7% |
| Q1 FY2022 | Mar 31, 2022 | -$81.00M | -2125.0% |
| Q4 FY2021 | Dec 31, 2021 | $124.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $64.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $132.00M | +266.7% |
| Q1 FY2021 | Mar 31, 2021 | $4.00M | -90.4% |
| Q4 FY2020 | Dec 31, 2020 | -$212.00M | -906.1% |
| Q1 FY2020 | Mar 31, 2020 | -$9.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $36.00M | -54.6% |
| Q3 FY2019 | Sep 30, 2019 | $41.60M | -71.5% |
| Q2 FY2019 | Jun 30, 2019 | $26.30M | -76.7% |
| Q1 FY2019 | Mar 31, 2019 | -$19.90M | -239.2% |
| Q4 FY2018 | Dec 31, 2018 | $79.30M | – |
| Q3 FY2018 | Sep 30, 2018 | $146.10M | – |
| Q2 FY2018 | Jun 30, 2018 | $113.10M | – |
| Q1 FY2018 | Mar 31, 2018 | $14.30M | – |
| Q4 FY2017 | Dec 31, 2017 | -$60.20M | – |
See a number that looks wrong?